Nakamura Tomoki, Takenaka Satoshi, Outani Hidetatsu, Hagi Tomohito, Tamiya Hironari, Imura Yoshinori, Asanuma Kunihiro, Sudo Akihiro
Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu 514-8507, Japan.
Musculoskeletal Oncology Service, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Cancers (Basel). 2024 Mar 6;16(5):1077. doi: 10.3390/cancers16051077.
Sarculator is a validated nomogram designed to predict overall survival (OS) in extremity soft tissue sarcoma (STS). Inflammation plays a critical role in cancer development and progression. There were no reports which investigated the relationship between Sarculator and inflammation.
A total of 217 patients with extremity STS were included. The Sarculator-predicted 10-year probability of OS (pr-OS) was stratified into two subgroups: lower risk (10-year pr-OS ≥ 60%) and higher risk (10-year pr-OS < 60%). The modified Glasgow prognostic score (mGPS) varied from 0 to 2.
Out of the 217 patients, 67 were classified as higher risk, while 150 were lower risk. A total of 181 patients had an mGPS of 0, and 36 had a score of 1 or 2. The 5-year OS was 83.3%. When patients were divided into two groups according to the 10-year pr-OS, those with a higher risk had poorer OS than those with a lower risk. Among the patients with a higher risk, those with an mGPS of 1 or 2 had poorer OS compared to those with a score of 0.
The mGPS could potentially play an important role in identifying patients who are at high risk of death and metastasis in the higher-risk group on the Sarculator.
Sarculator是一种经过验证的列线图，旨在预测肢体软组织肉瘤（STS）的总生存期（OS）。炎症在癌症的发生和发展中起着关键作用。目前尚无关于Sarculator与炎症之间关系的报道。
共纳入217例肢体STS患者。将Sarculator预测的10年OS概率（pr-OS）分为两个亚组：低风险（10年pr-OS≥60%）和高风险（10年pr-OS<60%）。改良格拉斯哥预后评分（mGPS）范围为0至2。
217例患者中，67例被归类为高风险，150例为低风险。共有181例患者的mGPS为0，36例患者的评分为1或2。5年OS率为83.3%。根据10年pr-OS将患者分为两组时，高风险组患者的OS比低风险组患者差。在高风险组患者中，mGPS为1或2的患者的OS比评分为0的患者差。
mGPS可能在识别Sarculator高风险组中死亡和转移高风险患者方面发挥重要作用。
Zotero 插件
